Rebranding Highlights Next-Generation Biopsy Innovations Under a Single Identity

LA JOLLA, CA–November 17, 2025 – Corramedical, Inc. announced today that its name has changed to Virchow Medical, signaling a transformative new chapter for the industry leader in biological specimen stewardship.  The name unifies the company’s identity and the name of its new Liquid Companion Specimen (LCS) biobank, the Virchow Vault.

Rudolf Virchow, MD lived from 1821 to 1902.  Referred to as the “Father of Modern Pathology,” in 1858, he wrote and published Cellular Pathology, declaring that disease originates in cells, establishing the rationale for tissue examination.  This is regarded to have been the insight that created the modern field of Pathology, and opened pathways to bacteriology and genetics.  He spent the next 44 years as a tireless medical innovator and advocate for integrating science, medicine, and social progress.  Today, 167 years later, Virchow Medical Inc. honors Virchow’s contributions by carrying on his mission, by providing products that allow healthcare providers and clinical laboratories to be good stewards of their patients’ biological material. Virchow Medical products are designed to collect cells that would otherwise have been medical waste, and instead use them to create new specimens with enormous clinical benefits.

“Virchow Medical’s new name reflects its opportunity to integrate medicine, science, and social progress toward improving human health in cancer therapeutics,” said Virchow Medical CEO Alexander Arrow, MD, CFA.  “Our corporate principles align with Dr. Virchow’s love of empirical evidence and his emphasis on the cell.  We believe more patients should benefit from genomic and multiomic evidence.  Our products collect cells to make that possible. We are standing on Virchow’s shoulders: the cellular model of disease, the ethical duty of public health, and the moral premise that science exists to serve society.”

Although first known as the inventor of cellular pathology, Dr. Virchow was also a tireless medical innovator and advocate for integrating medical science with social progress. He is now recognized as one of the earliest thinkers to integrate biology, ethics, and governance into a coherent vision of human progress.

“If Rudolf Virchow had been able to witness the modern-day wonders of targeted tumor therapy and genomic sequencing, he would have advocated for inventions that expand their availability to every cancer patient,” said Virchow Medical CTO Wilfrido Mojica, MD. “We are proud to be providing healthcare systems with products and services designed to do that.” 

Virchow Medical provides products that allow physicians and clinical laboratories to be effective, efficient stewards of their patients’ biological material. The company’s latest initiative, the Virchow Vault, is a unique biobank and data library that helps clinicians, researchers, and innovators better identify, design, and deliver targeted treatments.

“Clinical molecular testing laboratories, which didn’t exist in Dr. Virchow’s time, should attribute a part of their existence to his contributions to the field of pathology,” said Virchow Medical VP of Strategic Partnerships Shan Moledina. “We’ve applied these principles to today’s value-based care model, adapting it for advanced diagnostics like molecular tumor profiling.”

Along with its new corporate name, the company unveiled new logos for its four products:

The new logo of the Crow’s Nest® Biopsy Catchment System, the company’s flagship product, for use with core needle biopsy procedures, features a stylized nautical Crow’s Nest.

The logo of the Cell Wrangler,^TM, for use with fine needle aspiration procedures, features a stylized cowboy lasso.

The logo of the Multi-Omic Octagonal Scavenger or MOOS,^TM, the company’s third product, for use with excisional biopsy procedures, features a moose’s head and antlers. 

The logo of the Virchow Vault,^TM : The company’s fourth and latest product, a unique biobank that stores liquid specimens generated by Crow’s Nest and MOOS users, features a padlock and a strand of DNA.

All four product logos signify (1) standardization of specimen handling, (2) utilization of more of the cellular resources that are already being extracted from patients, (3) the reduction of attrition of patients in the “funnel” of oncology therapy trials, and (4) the expansion of targeted oncology therapy to a greater proportion of patients than who currently receive it.

About Virchow Medical, Inc.

Formerly known as Corramedical, Inc., Virchow’s mission is to provide clinicians with the tools they need to provide every biopsy patient the opportunity to be treated with precision medicine oncologic therapy.  The company creates novel collection products (the Crow’s Nest® Biopsy Catchment System, the Cell Wrangler^TM Fine Needle Aspirate Conserver, and the MOOS^TM Multi-Omic Octagonal Scavenger) to enable Liquid Companion Specimens (LCSs) to be made from material that would have otherwise been wasted, and a novel biorepository, the Virchow Vault,^TM to store them and make them available for testing. The company exists to enable healthcare providers and clinical laboratories to make use of all the cellular resources extracted from biopsy patients.

For further information, visit www.virchowmed.com, and follow Virchow on LinkedIn at https://www.linkedin.com/company/virchowmed/

Virchow Medical is an EvoNexus portfolio company.

Crow’s Nest^®, Virchow Vault^TM, Biopsy Catchment^TM, Cell Wrangler^TM, MOOS^TM, Sample Better^TM, The Waste is Over^TM, One Biopsy, Many Answers^TM, and Biopsy Specimen Stewardship^TM are trademarks of Virchow Medical, f/k/a Corramedical, Inc. 

Press contact: 

Nathan Edwards

Virchow Medical, f/k/a Corramedical, Inc.

9191 Towne Centre Drive

Suite 150

La Jolla, CA 92122

+1-833-4-BIOPSY, ext. 1

info@virchowmed.com

www.virchowmed.com.